We performed a single-arm, phase II trial of vandetanib in 18 adult patients with advanced NSCLC with RET rearrangement. The efficacy outcomes show an objective response rate of 18%, a disease control rate of 65%, a progression-free survival of 4.5 months, and an overall survival of 11.6 months during 14 months of follow-up indicating that vandetanib is moderately active in this population.
from Cancer via ola Kala on Inoreader http://ift.tt/2ftxgAF
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου